Last reviewed · How we verify

Betneval ointment - Non-desquamated zone

Galderma R&D · Phase 2 active Small molecule

Betneval ointment - Non-desquamated zone is a Small molecule drug developed by Galderma R&D. It is currently in Phase 2 development. Also known as: Betamethasone Valerate.

At a glance

Generic nameBetneval ointment - Non-desquamated zone
Also known asBetamethasone Valerate
SponsorGalderma R&D
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Betneval ointment - Non-desquamated zone

What is Betneval ointment - Non-desquamated zone?

Betneval ointment - Non-desquamated zone is a Small molecule drug developed by Galderma R&D.

Who makes Betneval ointment - Non-desquamated zone?

Betneval ointment - Non-desquamated zone is developed by Galderma R&D (see full Galderma R&D pipeline at /company/galderma-r-d).

Is Betneval ointment - Non-desquamated zone also known as anything else?

Betneval ointment - Non-desquamated zone is also known as Betamethasone Valerate.

What development phase is Betneval ointment - Non-desquamated zone in?

Betneval ointment - Non-desquamated zone is in Phase 2.

Related